Cargando…

Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report

INTRODUCTION: Chronic myelogenous leukemia is often treated using tyrosine kinase inhibitors such as dasatinib. Here we describe a rare case of inflammatory myopathy in a patient with chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib. CASE PRESENTATION: A 69-year-old...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlJohani, Naif I., Carette, Simon, Lipton, Jeffrey H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574179/ https://www.ncbi.nlm.nih.gov/pubmed/26376827 http://dx.doi.org/10.1186/s13256-015-0674-9

Ejemplares similares

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Dasatinib in chronic myeloid leukemia: a review
por: Aguilera, Dolly G, et al.
Publicado: (2009)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

The role of dasatinib in the management of chronic myeloid leukemia
por: Chen, Runzhe, et al.
Publicado: (2015)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
por: Lima, Lisa M, et al.
Publicado: (2010)

Dasatinib dose management for the treatment of chronic myeloid leukemia
por: Talpaz, Moshe, et al.
Publicado: (2018)

Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib
por: SahBandar, Ivo N., et al.
Publicado: (2023)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia
por: Poplausky, Dina, et al.
Publicado: (2023)

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
por: Haslam, Sonya
Publicado: (2005)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
por: Tarantini, Francesco, et al.
Publicado: (2019)

Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022)

A Case of Multiple Myeloma with Metachronous Chronic Myeloid Leukemia Treated Successfully with Bortezomib, Dexamethasone, and Dasatinib
por: Alsidawi, Samer, et al.
Publicado: (2014)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia
por: Yassin, Mohamed A, et al.
Publicado: (2015)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Optic neuropathy secondary to dasatinib in the treatment of a chronic myeloid leukemia case
por: Monge, Katia Sotelo, et al.
Publicado: (2015)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia
por: Adattini, Josephine A., et al.
Publicado: (2023)

Expanding dasatinib beyond KIT in acute myeloid leukemia
por: Welch, John S.
Publicado: (2020)

Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy
por: Serpa, Mariana, et al.
Publicado: (2010)

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

Reply: Comment on alemtuzumab and inclusion body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2010)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fpje95i15hh4n1holid7gjjnfr